Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli
Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few important restrictions/caveats that leave room for Apellis’s ...
U.S. ByteDance investors looking into TikTok U.S. deal, FT reports
The largest U.S. investors in TikTok owner ByteDance are looking into a deal alongside Oracle (ORCL) focused on assuring ...